查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472248

綜合代謝組測試市場：按測試類型、適應症和最終用戶分類：2023-2032 年全球機會分析和產業預測

Comprehensive Metabolic Panel Testing Market By Test Type, By Disease Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3個工作天內

價格

2022年綜合代謝組測試市場價值將達到101億美元，預計2032年將達到161億美元，2023年至2032年的複合年成長率為4.8%。

綜合代謝檢測 (CMP) 是一種測量血液中多種物質的血液檢查。全面的代謝組測試可測量血糖水平，從而表明血液中的糖分水平，用於診斷糖尿病和監測原有疾病。 CMP 測試還包括鈉、鉀和氯等電解質的測試。這些電解質對於維持體液平衡以及正常的神經和肌肉功能（包括收縮能力）非常重要。

綜合代謝組測試市場-IMG1

此外，CMP 測試透過測量個別血液中尿素氮 (BUN) 和肌酸酐的含量來研究腎功能，有助於及早發現腎臟問題。例如，丙胺酸胺基轉移酶(ALT) 和天門冬胺酸胺基轉移酶(AST) 都透過指示肝臟內發生的損傷或疾病來檢查肝臟健康狀況。總體而言，綜合代謝面板提供了關鍵生理過程的全面概述，並幫助醫療保健專業人員診斷和管理各種醫療狀況。

推動綜合代謝檢測市場成長的因素包括對診斷服務和糖尿病、心血管疾病和中風等慢性疾病的需求不斷增加，這些疾病需要準確、及時的診斷工具，例如 CMP 檢測。例如，根據美國疾病管制與預防中心 (CDC) 的數據，到 2022 年，美國每 10 名美國中就有 6 名患有糖尿病。因此，糖尿病、心血管疾病和腎臟疾病等疾病的盛行率不斷增加，需要定期切片檢查，從而推動市場成長。

此外，醫療意識的提高和篩檢計畫的提高也極大地促進了對綜合代謝組（CMP）測試的需求。隨著預防性醫療保健在公共衛生工作中的重要性日益增加，它已成為教育人們定期檢查的好處的重要組成部分。此類系統促進早期發現和早期療育，從而培養積極主動的醫療管理習慣並促進市場成長。此外，向預防性醫療保健的轉變是推動綜合代謝檢測市場成長的關鍵因素。隨著醫療保健的發展，人們越來越重視及時醫療保健和早期診斷，這一趨勢鼓勵個人定期進行健康檢查，並在潛在疾病出現更嚴重的情況之前發現它們，我們優先考慮識別健康風險並推動市場成長。

此外，不斷成長的老年人口也增加了對醫療保健和診斷測試的需求。老年人更容易患糖尿病、心臟病和腎臟病等慢性疾病，因此需要更頻繁的健康檢查和全面的代謝計劃來監測整體健康狀況並管理慢性疾病。提供全面生化資訊的綜合組織學檢查對於維持老年人健康和管理這些疾病非常重要。

然而，個人和醫療保健提供者缺乏認知是擴大綜合代謝組測試領域的主要障礙。此外，醫療保健行業嚴格的監管要求和合規標準給實驗室和診斷服務供應商帶來了挑戰，阻礙了市場成長。相較之下，就地檢驗的擴展可以在現場快速獲得結果，為醫療保健專業人員提供便利和更快的決策。市場開拓和採用 CMP 測試作為照護現場解決方案的一部分，尤其是在分散的醫療保健環境中，為市場成長提供了利潤豐厚的機會。

綜合代謝組測試市場按測試類型、疾病適應症、最終用戶和地區進行細分。依測試類型，市場分為蛋白質、電解質、腎臟測試、肝臟測試等。依適應症分為腎臟病、肝病、糖尿病等。依最終用戶分類，可分為醫院、診斷實驗室等。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年綜合代謝面板測試市場分析的細分市場、當前趨勢、估計和動態的定量分析，並確定了主導的綜合代謝面板測試市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 對綜合代謝組測試市場區隔的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並可以清楚地了解市場參與者的當前地位。
  • 該報告包括對區域和全球綜合代謝面板測試市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

此報告可以客製化（請聯絡銷售人員以了解額外費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 十字交叉細分市場分析 - 市場規模與預測
  • 公司簡介的擴充列表
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章綜合代謝組測試市場：依測試類型

  • 概述
  • 蛋白質
  • 電解質
  • 腎臟測試
  • 肝臟檢查
  • 其他

第5章綜合代謝組測試市場：按適應症疾病

  • 概述
  • 腎臟疾病
  • 肝病
  • 糖尿病
  • 其他

第6章綜合代謝面板測試市場：依最終用戶分類

  • 概述
  • 醫院
  • 診斷實驗室
  • 其他

第7章綜合代謝組測試市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • GCC
    • 南非
    • 北非
    • 其他中東/非洲

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Quest Diagnostics
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Walk-In Lab, LLC.
  • Applied InGENuity Diagnostics
  • Scion Lab Services, LLC
  • Baptist Health
  • My Care Labs
  • Blueprint Genetics
Product Code: A269963

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Comprehensive Metabolic Panel Testing Market - IMG1

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Proteins
  • Electrolytes
  • Kidney Tests
  • Liver Tests
  • Others

By Disease Indication

  • Kidney Diseases
  • Liver Diseases
  • Diabtes
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Quest Diagnostics
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Walk-In Lab, LLC.
    • Applied InGENuity Diagnostics
    • Scion Lab Services, LLC
    • Baptist Health
    • My Care Labs
    • Blueprint Genetics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Proteins
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Electrolytes
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Kidney Tests
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Liver Tests
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Kidney Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Liver Diseases
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Diabetes
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Test Type
    • 7.2.3. Market size and forecast, by Disease Indication
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Test Type
      • 7.2.5.1.2. Market size and forecast, by Disease Indication
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Test Type
      • 7.2.5.2.2. Market size and forecast, by Disease Indication
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Test Type
      • 7.2.5.3.2. Market size and forecast, by Disease Indication
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Test Type
    • 7.3.3. Market size and forecast, by Disease Indication
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Test Type
      • 7.3.5.1.2. Market size and forecast, by Disease Indication
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Test Type
      • 7.3.5.2.2. Market size and forecast, by Disease Indication
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Test Type
      • 7.3.5.3.2. Market size and forecast, by Disease Indication
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Test Type
      • 7.3.5.4.2. Market size and forecast, by Disease Indication
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Test Type
      • 7.3.5.5.2. Market size and forecast, by Disease Indication
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Test Type
      • 7.3.5.6.2. Market size and forecast, by Disease Indication
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Test Type
    • 7.4.3. Market size and forecast, by Disease Indication
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Test Type
      • 7.4.5.1.2. Market size and forecast, by Disease Indication
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Test Type
      • 7.4.5.2.2. Market size and forecast, by Disease Indication
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Test Type
      • 7.4.5.3.2. Market size and forecast, by Disease Indication
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Test Type
      • 7.4.5.4.2. Market size and forecast, by Disease Indication
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Test Type
      • 7.4.5.5.2. Market size and forecast, by Disease Indication
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Test Type
      • 7.4.5.6.2. Market size and forecast, by Disease Indication
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Test Type
    • 7.5.3. Market size and forecast, by Disease Indication
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Test Type
      • 7.5.5.1.2. Market size and forecast, by Disease Indication
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Test Type
      • 7.5.5.2.2. Market size and forecast, by Disease Indication
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Test Type
      • 7.5.5.3.2. Market size and forecast, by Disease Indication
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Test Type
      • 7.5.5.4.2. Market size and forecast, by Disease Indication
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Test Type
    • 7.6.3. Market size and forecast, by Disease Indication
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Test Type
      • 7.6.5.1.2. Market size and forecast, by Disease Indication
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Test Type
      • 7.6.5.2.2. Market size and forecast, by Disease Indication
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Test Type
      • 7.6.5.3.2. Market size and forecast, by Disease Indication
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Test Type
      • 7.6.5.4.2. Market size and forecast, by Disease Indication
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Quest Diagnostics
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Laboratory Corporation of America Holdings
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. ARUP Laboratories
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Walk-In Lab, LLC.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Applied InGENuity Diagnostics
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Scion Lab Services, LLC
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Baptist Health
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. My Care Labs
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Blueprint Genetics
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 02. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 08. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 41. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 82. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 83. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 85. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 91. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 92. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 94. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 95. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 96. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 99. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 101. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. QUEST DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 107. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 108. QUEST DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 109. QUEST DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 110. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 111. QUEST DIAGNOSTICS: KEY STRATERGIES
  • TABLE 112. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
  • TABLE 113. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 114. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
  • TABLE 115. LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE SEGMENTS
  • TABLE 116. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 117. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 118. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 119. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 120. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 121. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 123. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 124. ARUP LABORATORIES: KEY EXECUTIVES
  • TABLE 125. ARUP LABORATORIES: COMPANY SNAPSHOT
  • TABLE 126. ARUP LABORATORIES: PRODUCT SEGMENTS
  • TABLE 127. ARUP LABORATORIES: SERVICE SEGMENTS
  • TABLE 128. ARUP LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 129. ARUP LABORATORIES: KEY STRATERGIES
  • TABLE 130. WALK-IN LAB, LLC.: KEY EXECUTIVES
  • TABLE 131. WALK-IN LAB, LLC.: COMPANY SNAPSHOT
  • TABLE 132. WALK-IN LAB, LLC.: PRODUCT SEGMENTS
  • TABLE 133. WALK-IN LAB, LLC.: SERVICE SEGMENTS
  • TABLE 134. WALK-IN LAB, LLC.: PRODUCT PORTFOLIO
  • TABLE 135. WALK-IN LAB, LLC.: KEY STRATERGIES
  • TABLE 136. APPLIED INGENUITY DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 137. APPLIED INGENUITY DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 138. APPLIED INGENUITY DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 139. APPLIED INGENUITY DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 140. APPLIED INGENUITY DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 141. APPLIED INGENUITY DIAGNOSTICS: KEY STRATERGIES
  • TABLE 142. SCION LAB SERVICES, LLC: KEY EXECUTIVES
  • TABLE 143. SCION LAB SERVICES, LLC: COMPANY SNAPSHOT
  • TABLE 144. SCION LAB SERVICES, LLC: PRODUCT SEGMENTS
  • TABLE 145. SCION LAB SERVICES, LLC: SERVICE SEGMENTS
  • TABLE 146. SCION LAB SERVICES, LLC: PRODUCT PORTFOLIO
  • TABLE 147. SCION LAB SERVICES, LLC: KEY STRATERGIES
  • TABLE 148. BAPTIST HEALTH: KEY EXECUTIVES
  • TABLE 149. BAPTIST HEALTH: COMPANY SNAPSHOT
  • TABLE 150. BAPTIST HEALTH: PRODUCT SEGMENTS
  • TABLE 151. BAPTIST HEALTH: SERVICE SEGMENTS
  • TABLE 152. BAPTIST HEALTH: PRODUCT PORTFOLIO
  • TABLE 153. BAPTIST HEALTH: KEY STRATERGIES
  • TABLE 154. MY CARE LABS: KEY EXECUTIVES
  • TABLE 155. MY CARE LABS: COMPANY SNAPSHOT
  • TABLE 156. MY CARE LABS: PRODUCT SEGMENTS
  • TABLE 157. MY CARE LABS: SERVICE SEGMENTS
  • TABLE 158. MY CARE LABS: PRODUCT PORTFOLIO
  • TABLE 159. MY CARE LABS: KEY STRATERGIES
  • TABLE 160. BLUEPRINT GENETICS: KEY EXECUTIVES
  • TABLE 161. BLUEPRINT GENETICS: COMPANY SNAPSHOT
  • TABLE 162. BLUEPRINT GENETICS: PRODUCT SEGMENTS
  • TABLE 163. BLUEPRINT GENETICS: SERVICE SEGMENTS
  • TABLE 164. BLUEPRINT GENETICS: PRODUCT PORTFOLIO
  • TABLE 165. BLUEPRINT GENETICS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPREHENSIVE METABOLIC PANEL TESTING MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022